just like NEU hey 007. Although there was a lot of risk until...

just like NEU hey 007. Although there was a lot of risk until last year as it was waiting for a successful Phase 3 trial. Now NEU has a drug on the market making heaps of money, it is derisked and any other successful trials they complete are cream on the top - so still plenty of upside. EYE are in a similar position as we have a device FDA approved and making money and gaining more market share all the time, and now the Medicare rebate debate has disappeared, we are in great shape. If 2RT gets a partnership deal then the SP will be much more than where we are now and if it successfully gets to market, we will all be high fiving and paying off mortgages like the long termers at NEU. I only have a small investment in NUE at $1.87 buy in, I won’t make that mistake with EYE. Good luck all.